Scandinavian journal of gastroenterology
-
Scand. J. Gastroenterol. · Jun 2017
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore, we aimed to describe a vedolizumab-treated patient population and assess long-term effectiveness. ⋯ Vedolizumab-treated patients represent a treatment-refractory group. A long-term effect can be achieved, even beyond 1 year of treatment.
-
Scand. J. Gastroenterol. · Jun 2017
CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways.
As the alternate receptor for stromal cell-derived factor-1 (SDF-1) except CXCR4, CXCR7 has been shown to be involved in the progression of some malignancies. However, the role of SDF-1/CXCR7 in gastric cancer (GC) remains unclear. ⋯ CXCR7 was identified as a novel promoter in GC initiation and progression.